A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients.
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
Price : $35 *
At a glance
- Drugs Somatostatin (Primary) ; Octreotide
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms POC
- Sponsors Italfarmaco
- 31 Aug 2018 Biomarkers information updated
- 15 Jun 2016 Status changed from active, no longer recruiting to completed.
- 31 May 2016 The trial was completed in Italy (end date:2016-02-08).